VEGA-1 Phase 2 trial: Phentolamine Ophthalmic Solution Maintains Pupillary Reflex with Improved Distance-Corrected Near Vision in Presbyopes
Phentolamine Ophthalmic Solution 0.75%
Presented at American Society of Cataract and Refractive Surgery 2023
Filter by:
MIRA-4 Phase 3 Trial: The Safety and Efficacy of Phentolamine Ophthalmic Solution for Reversal of Pharmacologically Induced Mydriasis in Subjects Aged 3-11 Years
Phentolamine Ophthalmic Solution 0.75%
Presented at American Society of Cataract and Refractive Surgery 2023
ZETA-1 Phase 2 Trial Safety and Tolerability Results for APX3330: A Novel, Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy
APX3330
Presented at Association for Research in Vision and Ophthalmology 2023
Phentolamine Ophthalmic Solution with and without Low Dose Pilocarpine Provides Durable Improvement in Distance Corrected Near Vision for Presbyopic Patients: A Responder Analysis
APX3330
Presented at Association for Research in Vision and Ophthalmology 2023
VEGA-1 Phase 2 Trial: Phentolamine Ophthalmic Solution Maintains Pupillary Light Reflex with Improved Distance- Corrected Near Visual Acuity in Presbyopes
Phentolamine Ophthalmic Solution 0.75%
Presented at Association for Research in Vision and Ophthalmology 2023
Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically-Induced Mydriasis in 2 Pivotal Phase 3 Trials
Phentolamine Ophthalmic Solution 0.75%
Presented at Association for Research in Vision and Ophthalmology 2023
LYNX-1: A Phase 3 Randomized Placebo-Controlled Clinical Trial of Phentolamine Ophthalmic Solution in Subjects with Dim Light Vision Disturbances
Phentolamine Ophthalmic Solution 0.75%
Presented at Association for Research in Vision and Ophthalmology 2023
Safety and Efficacy of an Oral Therapeutic APX3330 from ZETA-1 Phase 2 Trial in Patients with Diabetic Retinopathy
APX3330
Presented at the Macula Society 46th Annual Meeting
Efficacy and Safety Data for APX3330, a Novel Oral Drug Candidate for DR/DME from the ZETA-1 Phase 2b Trial
APX3330
Bascom Palmer Eye Institute
Favorable Safety and Tolerability Profile of Oral APX3330 Drives Dosing Strategy for Ongoing Phase 2 Trial for DR/DME
APX3330
Presented at American Academy of Ophthalmology 2021
